Home › Posts tagged Epidermal Growth Factor Receptor (EGFR)
Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

…

Read more ›

Tags: , , , , , , , ,

This is it: First blood test to detect EGFR gene mutations in NSCLC

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, Thasso Post, Theragenomic Medicine 1 Comment ↓

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

…

Read more ›

Tags: , , , , , , , , , , ,

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Read more ›

Tags: , , , , , , ,

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

…

Read more ›

Tags: , , , , , , ,

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

Posted on by by Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

…

Read more ›

Tags: , , , , , , ,

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Thasso Post No Comments ↓

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

…

Read more ›

Tags: , , , , , , , , , ,

thasso: donate

thasso: conditions

thasso: newest tweets

 

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

  • Gene that protects against osteoarthritis identified December 2, 2020
    Osteoarthritis is one of the most common problems associated with aging, and although there are therapies to treat the pain that results from the breakdown of the cartilage that cushions joints, there are no available therapies to modify the course of the disease.
  • Treating brain diseases now possible December 1, 2020
    Neurological diseases of the brain such as dementia, autism and schizophrenia are now a growing social problem. Nevertheless, studies on their definitive cause are still insufficient. Recently, a POSTECH research team has identified the mechanism in which such neurological diseases occur, thus solving the enigma to treating them.
  • Scientists identify new genetic MND risk factor in junk DNA December 1, 2020
    A new genetic risk factor for Motor Neurone Disease (MND), which if treated could halt or prevent the degenerative condition, has been identified in so-called 'junk DNA' by scientists at the University of Sheffield. The newly discovered genetic changes are present in up to one percent of MND patients.
  • Genomic analysis of mako shark reveals genes relating to tumor suppression in humans December 1, 2020
    Anecdotal reports claim that the incidence of cancer in sharks is very low, but there is not enough data to confirm this estimate categorically. A study published in the journal Genomics, however, presents strong evidence of anti-tumor activity in the genome of the Shortfin mako shark, Isurus oxyrinchus.
  • A large-scale tool to investigate the function of autism spectrum disorder genes November 30, 2020
    Scientists at Harvard University, the Broad Institute of MIT and Harvard, and MIT have developed a technology to investigate the function of many different genes in many different cell types at once, in a living organism. They applied the large-scale method to study dozens of genes that are associated with autism spectrum disorder, identifying how […]

RSS random science

Top